Skip to content

For adults with uncontrolled moderate-to-severe atopic dermatitis1

When topical prescription therapies only go so far

Severe Moderate Mild
See progress continue

Not an actual patient.
Individual results may vary.

Icon depicting a bar chart

See Proven Clinical Study Results

Efficacy and safety results from three randomized, double-blind, placebo-controlled trials

See Results
Graphic of MOA Play Button

Discover How Adbry Works

The first and only biologic to specifically target and
neutralize IL-13

Explore MOA
Adbry Advocate Logo

Learn About Access & Patient Support

Comprehensive patient support services through the Adbry™ Advocate™ Program including Nurse Advocate and Adbry™ Copay Program. Restrictions apply

Learn More
  • The first and only biologic developed to specifically target and neutralize IL-13 1

  • Adbry demonstrated long-term safety through 52 weeks 1

  • Adbry demonstrated significant skin clearance, improvements in lesion extent and severity, and itch relief at week 16 1-4

  • The flexibility to treat with every-other-week dosing or every-4-week dosing after 16 weeks of treatment (for patients with body weight <100 kg who achieve clear or almost clear skin)1

  • Adbry achieved lasting disease control at Weeks 32 and 52 1

Adbry has no boxed warning and no requirement for initial lab testing of ongoing lab monitoring in the Prescribing Information


References: 1. Adbry Prescribing Information, LEO Pharma. 2. Silverberg JI, Toth D, Bieber T, et al; ECZTRA 3 study investigators. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol. 2021;184(3):450-463. 3. Wollenberg A, Blauvelt A, Guttman-Yassky E, et al; ECZTRA 1 and ECZTRA 2 study investigators. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184(3):437-449. doi:10.1111/bjd.19574. 2021. 4. Data on File. LEO Pharma.